ADVENTRX Pharmaceuticals announces 6-month balance data for Exelbine ADVENTRX Pharmaceuticals, Inc. The 6-month balance data are on the right track to aid the submission of the New Drug Program for Exelbine. Culley, Chief Executive Officer of ADVENTRX. Once we have the 12-month data, we shall submit the Exelbine NDA, which we expect will need place in the fourth quarter of the year. .The ASPIRE study shows that for every 1000 sufferers treated for 12 months, aspirin can be expected to end up being connected with 17 fewer episodes of recurrent venous thromboembolism and 28 fewer major thrombotic occasions, at the expense of 5 nonfatal bleeding episodes. In conclusion, the findings of the ASPIRE study, especially when considered together with data from the WARFASA study, provide constant evidence that low-dose aspirin is beneficial in preventing recurrent venous thromboembolism and major vascular events in individuals who’ve had a first bout of unprovoked venous thromboembolism.